Potential of interferon-alpha in solid tumours: part 1

Area of Science:

• Oncology
• Immunology
• Biotechnology

Background:

• Interferon-alpha (IFNalpha) is a cytokine with direct and indirect antitumor effects, including cell cycle arrest, apoptosis induction, and immunomodulation.
• Recombinant IFNalpha (rIFNalpha) has been extensively studied in solid tumors since the advent of genetic engineering.

Purpose of the Study:

• This review evaluates the efficacy and potential of rIFNalpha in solid tumors, focusing on malignant melanoma and metastatic renal cell carcinoma (RCC).

Main Methods:

• Analysis of randomized trials and meta-analyses evaluating adjuvant and metastatic rIFNalpha in malignant melanoma and RCC.
• Review of clinical trial data, including response rates, disease-free survival (DFS), and overall survival (OS).

Main Results:

• High-dose adjuvant rIFNalpha (≥10MU) prolongs DFS in malignant melanoma but not OS. Low-dose (<3MU) showed no significant benefit.
• Adjuvant rIFNalpha is not supported by current evidence for RCC.
• Response rates in metastatic melanoma and RCC are approximately 15%, with potential for long-standing responses in a subset of patients.
• Combination therapy in metastatic melanoma showed high response rates but no survival improvement.
• In metastatic RCC, prolonged therapy (>12 months) with intermediate dosages of rIFNalpha may be beneficial, influenced by prognostic factors.

Conclusions:

• High-dose rIFNalpha offers a DFS benefit in adjuvant malignant melanoma treatment, but its impact on OS remains unproven.
• Current data do not support adjuvant rIFNalpha for RCC.
• The role of rIFNalpha in advanced melanoma and RCC requires further investigation with ongoing studies.